ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Amgen hands back heart failure programme rights to Cytokinetics
November 25, 2020Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study. -
Amgen Ends Cardio Alliance with Cytokinetics
November 24, 2020Amgen has terminated its collaboration with Cytokinetics and intends to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.
Pharma Sources Insight January 2025
